new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Cephalon Inc patents

Recent patent applications related to Cephalon Inc. Cephalon Inc is listed as an Agent/Assignee. Note: Cephalon Inc may have other listings under different names/spellings. We're not affiliated with Cephalon Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cephalon Inc-related inventors




Date Cephalon Inc patents (updated weekly) - BOOKMARK this page
03/23/17Antibodies that specifically bind to tl1a
03/16/17Novel solid forms of bendamustine hydrochloride
02/02/17Macrocyclic compounds as alk, fak and jak2 inhibitors
02/02/17Substituted aromatic sulfur compounds and methods of their use
12/22/161,4-substituted piperidine derivatives
12/01/16Pyrrolotriazines as alk inhibitors
11/03/16Pyrazolo[1,5-a]pyridine derivatives and methods of their use
10/20/16Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
08/25/16Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
06/09/16Novel solid forms of bendamustine hydrochloride
03/10/16Pyrrolotriazines as alk inhibitors
01/07/16Child resistant cover for oral dosage forms
01/07/16Nanoparticulate and macroparticulate formulations
12/31/15Bendamustine pharmaceutical compositions
12/31/15Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
12/24/15Tricyclic derivatives and their pharmaceutical use and compositions
11/26/15Liquid formulations of bendamustine
02/19/15Novel solid forms of bendamustine hydrochloride
01/08/15Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
01/08/15Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
10/30/14Thienopyrimidine inhibitors of atypical protein kinase c
10/02/14Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
09/18/14Uracil derivatives as axl and c-met kinase inhibitors
09/18/14Solid state forms of 6-[4-[3-((r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl] 2h-pyridazine-3-one hydrochloride
07/24/14Liquid formulations of bendamustine
07/03/14Novel solid forms of bendamustine hydrochloride
05/29/14Bendamustine pharmaceutical compositions
05/22/14Pyridazinone derivatives
05/08/14Liquid formulations of bendamustine
05/01/14Proteasome inhibitors and processes for their preparation, purification and use
04/24/14Azaquinazoline inhibitors of atypical protein kinase c
03/27/14Proteasome inhibitors and methods of using the same
03/20/14Liquid formulations of bendamustine
01/30/14Macrocyclic compounds as alk, fak and jak2 inhibitors
01/23/14Janus kinase 2 (jak2) inhibitor for the treatment of lupus
12/26/13Proteasome inhibitor delanzomib for use in the treatment of lupus
12/19/13Bendamustine pharmaceutical compositions
11/21/13Methods for the preparation of bendamustine
11/21/13Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
09/19/13Novel solid forms of bendamustine hydrochloride
06/20/13Modafinil formulations
06/06/13Methods for the sterilization of bendamustine
05/16/13Method for purifying a fused pyrrolocarbazole derivative
04/18/13Modafinil compositions
12/20/12Pharmaceutical formulations of modafinil
12/13/12Pharmaceutical formulations of modafinil
11/22/12Tricyclic derivatives and their pharmaceutical use and compositions
11/01/12Tricyclic derivatives and their pharmaceutical use and compositions
10/25/12Proteasome inhibitors and processes for their preparation, purification and use
09/20/12Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
08/23/12Novel forms of a multicyclic compound
06/28/12Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
06/21/12Oral formulations of bendamustine
05/24/12Liquid formulations of bendamustine
04/05/12Surface-treated modafinil particles
03/29/12Composition for transmucosal delivery of polypeptides
03/22/12Combination therapy for the treatment of multiple myeloma
03/22/12Novel solid forms of bendamustine hydrochloride
02/16/12Proteasome inhibitors and methods of using the same
02/09/12Lyophilization cakes of proteasome inhibitors
02/02/12Pyrrolotriazines as alk and jak2 inhibitors
01/05/12Substituted pyridazine derivatives
01/05/12Novel fused pyrrolocarbazoles
11/24/11Pyridazinone derivatives
09/22/11Novel forms of a fused pyrrolocarbazole compound
Patent Packs
08/25/11Modafinil formulations
08/11/11Transmucosal treatment methods in patients with mucositis
08/04/11Liquid formulations of bendamustine
08/04/11Processes for the preparation of bendamustine
06/30/11Pyridopyrazines and derivatives thereof as alk and c-met inhibitors
06/16/11Proteasome inhibitors and methods of using the same
05/26/11Crystalline forms of a pharmaceutical compound
04/28/11Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
03/10/11Novel multicyclic compounds and the use thereof
03/03/11Substituted bicyclic pyrimidines
01/27/11Enhanced transmucosal composition and dosage form
12/09/10Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
12/09/10Substituted pyridazine derivatives
11/25/10Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
11/04/10Pyridazinone derivatives
Patent Packs
10/28/10Pyridazinone derivatives
08/19/10Novel forms of bendamustine free base
08/19/10Modafinil compositions
06/17/10Novel fused pyrrolocarbazoles
05/27/10Novel pharmaceutical formulations of modafinil
05/13/10Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
05/06/10Composition for transmucosal delivery of polypeptides
05/06/10Surface-treated modafinil particles
04/01/10Lyophilized pharmaceutical compositions and methods of making and using same
02/25/10Pyridopyrazines and derivatives thereof as alk and c-met inhibitors
12/24/09Modafinil formulations
11/26/09Proteasome inhibitors and methods of using the same
10/22/09Novel solid forms of bendamustine hydrochloride
09/10/09Novel crystalline forms of lestaurtinib
07/23/09Novel fused pyrrolocarbazoles
06/18/09Microemulsion containing indolocarbazole compound and dosage forms containing the same
03/19/09Proteasome inhibitors and methods of using the same
03/05/09Thio-substituted biarylmethanesulfinyl derivatives







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Cephalon Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cephalon Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';